Cytochrome P450 2B6 516G-->T is associated with plasma concentrations of nevirapine at both 200 mg twice daily and 400 mg once daily in an ethnically diverse population.
about
Population pharmacokinetic-pharmacogenetic study of nevirapine in HIV-infected Cambodian patientsPharmacokinetic, Pharmacogenetic, and Other Factors Influencing CNS Penetration of AntiretroviralsMeasuring the overall genetic component of nevirapine pharmacokinetics and the role of selected polymorphisms: towards addressing the missing heritability in pharmacogenetic phenotypes?Nevirapine once daily: pharmacology, metabolic profile and efficacy data of the new extended-release formulation.Nevirapine pharmacokinetics when initiated at 200 mg or 400 mg daily in HIV-1 and tuberculosis co-infected Ugandan adults on rifampicinCYP2B6 c.983T>C polymorphism is associated with nevirapine hypersensitivity in Malawian and Ugandan HIV populations.Comparison of nevirapine plasma concentrations between lead-in and steady-state periods in Chinese HIV-infected patients.Integration of population pharmacokinetics and pharmacogenetics: an aid to optimal nevirapine dose selection in HIV-infected individuals.Hypersensitivity reactions to HIV therapy.Chemokine (C-C motif) receptor 5 -2459 genotype in patients receiving highly active antiretroviral therapy: race-specific influence on virologic successFactors influencing plasma nevirapine levels: a study in HIV-infected children on generic antiretroviral treatment in IndiaEvaluation of adherence measures of antiretroviral prophylaxis in HIV exposed infants in the first 6 weeks of lifeCytochrome P450 2B6 genetic variants are associated with plasma nevirapine levels and clinical response in HIV-1 infected Kenyan women: a prospective cohort study.Exploration of CYP450 and drug transporter genotypes and correlations with nevirapine exposure in MalawiansPharmacogenomics of HIV therapy: summary of a workshop sponsored by the National Institute of Allergy and Infectious Diseases.Pharmacokinetics and safety of a new paediatric fixed-dose combination of zidovudine/lamivudine/nevirapine in HIV-infected children.Toxicogenomics of nevirapine-associated cutaneous and hepatic adverse events among populations of African, Asian, and European descentWorldwide variation in human drug-metabolism enzyme genes CYP2B6 and UGT2B7: implications for HIV/AIDS treatment.Individualization of antiretroviral therapy.Multiple genetic variants predict steady-state nevirapine clearance in HIV-infected Cambodians.Pharmacogenetics of cytochrome P450 2B6 (CYP2B6): advances on polymorphisms, mechanisms, and clinical relevanceSuboptimal nevirapine steady-state pharmacokinetics during intrapartum compared with postpartum in HIV-1-seropositive Ugandan women.Association of ABCC10 polymorphisms with nevirapine plasma concentrations in the German Competence Network for HIV/AIDSClinical and genetic determinants of plasma nevirapine exposure following an intrapartum dose to prevent mother-to-child HIV transmissionInfluence of CYP2B6 polymorphisms on the persistence of plasma nevirapine concentrations following a single intra-partum dose for the prevention of mother to child transmission in HIV-infected Thai women.Antiretroviral drug toxicity in relation to pharmacokinetics, metabolic profile and pharmacogenetics.HLA and pharmacogenetics of drug hypersensitivity.Pharmacogenetics of antiretroviral therapy.Role of dermatology in pharmacogenomics: drug-induced skin injury.Stevens-Johnson syndrome and toxic epidermal necrolysis: an update on pharmacogenetics studies in drug-induced severe skin reaction.Genetic Polymorphisms Affecting the Pharmacokinetics of Antiretroviral Drugs.Class-specific relative genetic contribution for key antiretroviral drugs.Lipid-based nutrient supplements do not affect efavirenz but lower plasma nevirapine concentrations in Ethiopian adult HIV patients.Clinical and genetic determinants of nevirapine plasma trough concentration.Physiologically based pharmacokinetic models for the optimization of antiretroviral therapy: recent progress and future perspectiveClinical and genetic factors associated with increased risk of severe liver toxicity in a monocentric cohort of HIV positive patients receiving nevirapine-based antiretroviral therapy
P2860
Q24602072-E812359B-1592-4761-B612-757C48E94107Q28069383-E0A709AA-659B-46FF-839F-9CED327F180BQ33720712-051A27B4-7029-4B01-8883-08AB78116C8EQ33850152-CA961D03-7D0D-440E-BE6B-7E69F67DF190Q34405883-4C265047-AEC5-4D6A-A80F-F40A7030D514Q34495636-43CABEAC-3779-4D86-AB9B-488BB08FBBB4Q34566233-221C5164-A1DA-429D-B532-5E296BC1B476Q34975110-7150C71A-92BB-44B8-849B-D09887AAF3AFQ34976463-000C14FE-DB07-495C-9BF5-83C31529268AQ35043700-15810BE5-56DF-4EB7-89FA-0E56828AE962Q35127567-FC6A4003-A2A4-4EA1-8233-72DD94D724C2Q35238134-B85AF520-2365-4D6D-B8D2-1A6D249E95FCQ35426496-80E1070D-40C4-496B-A765-10858C344D34Q35796733-7FB04DB0-5D98-444D-9CCA-F49979BA0731Q35878413-512BBA98-0718-4099-A3E7-7D81F0380710Q35947409-D4C3AFED-7127-4666-9923-96A5C1F2BD96Q36070182-E272A849-A9F2-4A8A-B705-4DC74228547AQ36079108-3BFA443F-112F-400B-8551-0387DC709B2AQ36441423-C05B2DF9-0D08-4274-A1B9-41481ADC86C4Q36650954-970D47B9-D20B-4F80-9E62-000316E5CBDDQ36657589-85E3834E-155D-468F-84F7-E4005E8857B2Q36676527-4C72DB40-EBAD-4C29-ACB8-ECAB6E42A061Q36708715-C460509E-FAA3-4596-B482-6D202F19B946Q37037070-DBBF53A3-FF5E-4AB0-8854-069671B519DAQ37417511-83D1477E-9524-4EA0-8509-D4D9FAE6E3FBQ37866298-81C4FCA8-13D0-413F-91FB-71A8237BE706Q38037649-BDD5A450-B453-4CC6-A5D4-A1F4051FDB36Q38221179-664DBDDA-D3B7-4C0A-9C16-97BA7C64D96FQ38396234-4B1125C1-F724-442B-A152-E5F312C1D348Q38629821-01F6E578-33DC-4803-8C4B-86D5F4D9D863Q38957969-D062391A-1A8F-4AB7-9B70-B51D1DEEDA3FQ38980007-AB9F6192-327E-492A-8A69-A94CF2BB8411Q40280595-83C5FE53-CE15-4A26-B10B-7B00281F16F3Q55263551-FEBEB668-CBA9-4279-A730-277BEA5C7BCAQ58073610-3E4DCEE5-DD13-40E8-8314-4C5C015A40BAQ59136209-D3DF79BF-3A20-4D74-8828-D9F3E445E924
P2860
Cytochrome P450 2B6 516G-->T is associated with plasma concentrations of nevirapine at both 200 mg twice daily and 400 mg once daily in an ethnically diverse population.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Cytochrome P450 2B6 516G-->T i ...... ethnically diverse population.
@en
Cytochrome P450 2B6 516G-->T i ...... ethnically diverse population.
@nl
type
label
Cytochrome P450 2B6 516G-->T i ...... ethnically diverse population.
@en
Cytochrome P450 2B6 516G-->T i ...... ethnically diverse population.
@nl
prefLabel
Cytochrome P450 2B6 516G-->T i ...... ethnically diverse population.
@en
Cytochrome P450 2B6 516G-->T i ...... ethnically diverse population.
@nl
P2093
P1433
P1476
Cytochrome P450 2B6 516G-->T i ...... ethnically diverse population.
@en
P2093
Ma Johnson
Tw Mahungu
P304
P356
10.1111/J.1468-1293.2008.00689.X
P50
P577
2009-02-17T00:00:00Z